Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity results of a prospective phase II trial

Annals of Surgery

Volumn 248, Issue 6, 2008, Pages 1014-1021

  Heinrich, Stefan ^a   Schäfer, Markus ^a   Weber, Achim ^b   Hany, Thomas F ^c   Bhure, Ujwal ^c   Pestalozzi, Bernhard C ^d   Clavien, Pierre Alain ^a,b  

^a Swiss HPB Center   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Division of Nuclear Medicine   (Switzerland)

^d Stadtspital Triemli   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE; GEMCITABINE; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; ENDOSCOPIC ECHOGRAPHY; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROSCOPY; MALE; METABOLISM; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; SURGICAL MORTALITY; THORAX RADIOGRAPHY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; MORTALITY; PANCREAS TUMOR; PROSPECTIVE STUDY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; MORBIDITY; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 58149383101     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318190a6da     Document Type: Article

References (31)

1. Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg. 2004;240:738-745.
2. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymph- adenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355-366.
3. Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385-287.
4. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/ computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-243.
5. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782.
6. GITSG. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
7. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297:267-277.
8. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N EnglJMed. 2004;350:1200-1210.
9. Chandler NM, Canete JJ, Stuart KE, et al. Preoperative chemoradiation in resectable pancreatic cancer. J Hepatobiliary Pancreat Surg. 2003; 10:61-66.
10. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-1339.
11. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for ade- nocarcinoma of the pancreatic head. Am J Surg. 1996;171:118-124; discussion 124 -125.
12. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998;16:317-323.
13. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradio- therapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8:123-132.
14. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245-3251.
15. Heinemann V, Schermuly MM, Stieber P, et al. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res. 1999;19:2433-2435.
16. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157-164.
17. Heinrich S, Pestalozzi B, Schafer M, et al. Prospective phase II trial on neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma ofthe pancreatic head. JClin Oncol. 2008;26:2526-2531.
18. Schafer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg. 2002;236:137-148.
19. Dindo D, Demartines N, Clavien P. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
20. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244: 931-937; discussion 937-939.
21. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur JNuclMed. 2000;27:731-743.
22. Greene FL. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol. 2003;21:23-29.
23. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005;65:10104-10112.
24. Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14:2088-2096.
25. Barugola G, Falconi M, Bettini R, et al. The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP. 2007; 8(suppl 1):132-140.
26. de Geus-Oei LF, van der Heijden HF, Corstens FH, et al. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654-1664.
27. Cullen KJ, Yang Z, Schumaker L, et al. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. JBioen- erg Biomembr. 2007;39:43-50.
28. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. 2007;7:10-18.
29. Kim SY, Roh JL, Kim MR, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx.
30. JNucl Med. 2007;48:752-757.
31. Cheng TY, Sheth K, White RR, et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenec- tomy. Ann Surg Oncol. 2006;13:66 -74.